To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00661115 |
Recruitment Status :
Completed
First Posted : April 18, 2008
Last Update Posted : December 16, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Erectile Dysfunction | Drug: Levitra (Vardenafil, BAY38-9456) Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 173 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Double Blind, Placebo Controlled, Multi-center, Fixed Dose, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil (BAY 38-9456) in Men With Erectile Dysfunction . |
Study Start Date : | May 2003 |
Actual Primary Completion Date : | February 2004 |
Actual Study Completion Date : | February 2004 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm 1 |
Drug: Levitra (Vardenafil, BAY38-9456)
Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks |
Placebo Comparator: Arm 2 |
Drug: Placebo
Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks |
- Erectile function (EF) domain score of the International Index of Erectile Function (IIEF)calculated as the sum of scores from Questions 1 to 5 and 15 [ Time Frame: At Week 12 using the Last Observation Carried Forward (LOCF) method to account for dropouts. ]
- Success in penetration and maintenance as recorded in subject diaries [ Time Frame: At Weeks 4, 8 and 12 (as observed and at LOCF) ]
- Scores for questions 3 and 4 of the IIEF [ Time Frame: At Weeks 4, 8 and 12 (as observed and at LOCF) ]
- Other IIEF domain scores [ Time Frame: At Week 12 (observed and at LOCF) ]
- Global Assessment Question (GAQ) responses [ Time Frame: At Weeks 4, 8 and 12 (as observed and at LOCF) ]
- Rates of premature termination, adverse events, laboratory abnormalities, ECG abnormalities, and concomitant medication use. [ Time Frame: At Weeks 4, 8 and 12 (as observed and at LOCF) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men 21 years or above with ED for more than 6 months with normal libido and stable heterosexual relationship of at least 6 months
- having at least a 50% failure rate of sexual intercourse attempts during the run-in phase
Exclusion Criteria:
- Subjects with penile abnormalities, hypogonadism, history of unstable angina pectoris for 6 months or less, myocardial infarction, life threatening arrhythmia and history of unresponsiveness to sildenafil were excluded.
- Diabetic subjects with hemoglobin A1c (HbA1c) more than 12% were also excluded.
- Subjects could not be on androgens/anti-androgens or alpha blockers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00661115
India | |
Bangalore, Karnataka, India, 560010 | |
Bangalore, Karnataka, India, 560054 | |
Belagum, Karnataka, India, 590010 | |
Mumbai, Maharashtra, India, 400007 | |
Mumbai, Maharashtra, India, 400022 | |
Madurai, Tamilnadu, India, 625107 |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer |
ClinicalTrials.gov Identifier: | NCT00661115 |
Other Study ID Numbers: |
10695 |
First Posted: | April 18, 2008 Key Record Dates |
Last Update Posted: | December 16, 2014 |
Last Verified: | December 2014 |
Erectile dysfunction Sexual Dysfunction |
Erectile Dysfunction Genital Diseases, Male Genital Diseases Urogenital Diseases Sexual Dysfunction, Physiological Male Urogenital Diseases Sexual Dysfunctions, Psychological Mental Disorders |
Vardenafil Dihydrochloride Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents |